NewAmsterdam Pharma Co N.V. - 8-K Filing

NewAmsterdam Pharma receives positive CHMP opinion for Ubeslo® (obicetrapib monotherapy) and Evlarco® (obicetrapib/ezetimibe FDC), with EC decision expected in H2 2026. (Items: 8.01 Other Events, 9.01 Financial Statements and Exhibits)

SEC EDGAR ·

Tickers: $NAMS

Read the full article at SEC EDGAR

More Regulatory news